Trials

BMX Alpha is a prospective, multi-center, registry designed to enrol 400 patients to 12 international centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data collection. Major adverse cardiac events (MACE) results at 9 months...

The ContraBand™ device is intended for treatment of heart failure patients who remain symptomatic despite the use of optimally tolerated guideline directed medical therapy.

The R-OneTM robotic platform is currently indicated for remote delivery and manipulation of coronary guidewires and stent/balloon devices during percutaneous coronary interventions. Robocath is seeking to expand the indication for use to include the common carotid artery, commonly classified as part...

R-One registry (CHANGE) is a single-arm, open-label, multi-center subject registry in Europe and South Africa of the R-oneTM to examine its performance during PCI procedures at hospital discharge, whichever occurs first. ID: NCT05853419

This is a prospective, multicenter, exploratory single arm and controlled clinical investigation compared to recent historical results. This pre-CE marked trial is conducted in two countries (France and the UK) with 5 Investigation sites participate to the trial. The recruitment was finalized in...

This is a multi­centre, single-blind, prospective randomized investigator-driven trial that will include 2100 patients in 10 countries. Included patients will present a high-risk for restenosis due to clinical profile or coronary lesion complexity and will undergo elective or emergent percutaneous...

An Investigator-initiated, multi-center, randomized controlled trial to compare the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high bleeding risk. ID: NCT04500912

This is an investigator initiated multi-center, open-label, randomized (1:1) controlled trial comparing Prasugrel-based short (30-45 days) Dual-Antiplatelet-Therapy (DAPT) followed by Prasugrel monotherapy versus standard 12-month DAPT regimen in 1656 STEMI patients. ID: NCT05491200

An international, multicenter, prospective, randomized clinical investigation to evaluate the safety and effectiveness of the Conformal CLAAS System for left atrial appendage occlusion, in comparison to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in...

Cruz HBR Registry is post-market, prospective, multi-center, open-label, single-arm registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease by Percutaneous Coronary Intervention...